Ahead of disease

Innovation is at the heart of achieving our purpose – to unite science, technology and talent to get ahead of disease together.

How our R&D approach helps us get Ahead Together

There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
Portrait of Tony Wood

Tony Wood

Chief Scientific Officer-designate

We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.

We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.

  • Our R&D investment in 2022

  • An outstanding R&D team of

Canada's Top  100 Corporate R&D Spenders | 2023 | Research Infosource Inc.

A Canadian R&D Leader

We are one of the largest research and development (R&D) organizations in Canada. We have invested $89 million in Canadian research and development (R&D) in 2021.

Canada's Top 100 Corporate R&D Spenders

Supporting R&D innovation in Canada

To accelerate the discovery of new medicines and vaccines, we make collaboration part of our business model. Partnering with academic researchers and public organizations is a key part of our research efforts and we have a range of projects in place to allow us to work with and support new projects that fall within the specific areas of science we are interested in exploring.

In Canada, GSK is actively engaged in the support of research and innovation in the life sciences, and the commercialization of new technologies. GSK Canada works actively with academic researchers, university industry liaison and technology transfer offices, and innovation hubs such as the Quebec Consortium for Drug Development (CQDM) to investigate new therapeutic targets as well as disruptive platforms for discovery and development.

Our pipeline

As a global biopharma company, we invest heavily in our industry-leading pipeline of new products and specialty medicines that help us to get ahead of disease together.

Half of a 3D rendering of a Covid virus cell
potential vaccines and medicines
of these products modulate the immune system
the number of assets in phase III clinical development during last 5 years

Therapeutic areas

The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, oncology and immunology.

We remain open to opportunities outside these core areas where the science aligns with our strategic approach.


Therapy areas

We are at the forefront of health-related advances in science and technology, working to create innovative solutions to a range of healthcare challenges.

Advanced technology platforms such as AI, machine learning and functional genomics are central to our R&D approach. At the same time, diverse vaccine platform technologies including the use of adjuvants and mRNA technology have the potential to drive the next generation of vaccines and medicines. 


Explore how we apply technology to R&D on our global site

Diseases and medicines can affect people differently depending on their race, ethnicity, sex or age. It’s therefore vital that we represent the real-world disease population in our clinical trials to advance our understanding of new vaccines and medicines, to create better health outcomes for the patients who rely on us.

Find out about our clinical trials process, how we work with doctors and volunteers throughout this process, and how to become a research volunteer.

Clinical trials

Our leading R&D centres in the UK, US, Belgium and Italy are pivotal in helping us to get ahead of disease around the world.

Explore our global R&D locations